Google
DCTH 株価分析 — Delcath Systems Inc (Healthcare >> Medical Devices)
DCTH に関するよくある質問
DCTHのPER（株価収益率）は？
Delcath Systems Inc（DCTH）は現在PER 117.85倍で取引されています。
DCTHのROE（自己資本利益率）は？
Delcath Systems IncのROEは0.50%です。
DCTHの配当利回りは？
Delcath Systems Incの配当利回りは0.00%です。
DCTHの品質スコア（Quality Score）は？
当社のAIはDCTHの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
DCTHは今が買い時ですか？
当社AIのタイミングスコアは100点中70点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
DCTHはどのセクターに属しますか？
Delcath Systems IncはHealthcare >> Medical Devicesセクターに分類されます（NASDAQ市場）
DCTH AI Analysis Summary
Our AI summary for DCTH: Delcath Systems Inc (NASDAQ), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 117.85, ROE of 0.50%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 70/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 12.22
Price
0.18
(1.50%)
Day Change
|
|
|---|
DCTH, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
2879
|
| Magic Formula Rank by ROE |
2879
|
| Magic Formula Rank by ROIC |
1613
|
| Price | 12.22 |
| PBV / Sector |
3.69 / -101.57
|
| Earning Per Share | 0.02 |
| PE / Sector |
117.85 / 31.23
|
| PEG or PE/Growth / Sector |
-1.73 / 0.40
|
| Average 1M Daily Value |
4.34 M
GREAT
|
| Average 1W Daily Value |
4.64 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:42 |
| Symbol | DCTH |
| Name | DELCATH SYSTEMS INC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 34.52 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 415.64 / 20,104.97 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 566 Queensbury Avenue, Queensbury, NY, United States, 12804
Phone: 212 489 2100
Website: https://www.delcath.com
Employees: 156
Sector: Healthcare >> Medical Devices
Description: Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
